---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-054876"
form_type: "8-K"
ticker: "HIND"
cik: "0001427570"
company_name: "Vyome Holdings, Inc"
filed_at: "2025-05-30T23:59:59+00:00"
generated_at: "2026-05-20T04:12:49.217206+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ReShape Lifesciences enters $9.7M at-the-market equity distribution agreement with Maxim Group

## Summary
- Agreement allows sale of up to $9.7M of common stock via ATM offering; effective May 30, 2025.
- Maxim receives 3.0% commission on gross proceeds plus up to $50K legal fee reimbursement and $3K per due diligence session.
- Shares sold under existing effective S-3 shelf registration (File No. 333-287168).
- Company has no obligation to sell; offering ends upon sale of $9.7M or termination by either party.

## SEC filing metadata
- accession: 0001104659-25-054876
- form_type: 8-K
- ticker: HIND
- cik: 0001427570
- company_name: Vyome Holdings, Inc
- filed_at: 2025-05-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427570/000110465925054876/0001104659-25-054876-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427570/000110465925054876/tm2516583d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-054876
- JSON: https://secwatch.observer/filing/0001104659-25-054876.json
- Plain text: https://secwatch.observer/filing/0001104659-25-054876.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.